MedTrace Logo

A Study of DA-302168S in Participants With Overweight/Obesity

NCT07629544 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 840

Last updated 2026-08-06

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.

Conditions

  • Overweight and Obesity

Interventions

DRUG

DA-302168S

A small molecule GLP-1R agonist tablet, orally administration, once daily

DRUG

DA-302168S

A small molecule GLP-1R agonist tablet, orally administration, once daily

DRUG

Placebo

Matching placebo tablet will be provided

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Chendu DIAO Pharmaceutical Group CO., LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-19
Primary Completion
2027-07-09
Completion
2027-10-19

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629544 on ClinicalTrials.gov